|Bid||25.63 x 800|
|Ask||34.20 x 800|
|Day's range||23.65 - 25.87|
|52-week range||15.58 - 48.40|
|Beta (5Y monthly)||1.07|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
FRIENDSWOOD, Texas, November 21, 2022--Castle announced that the Accreditation Committee of the College of American Pathologists (CAP) has accredited its clinical laboratory in Pittsburgh.
FRIENDSWOOD, Texas, November 17, 2022--Castle announced the publication of a study in collaboration with the MRF to assess patient experiences with prognostic testing in uveal melanoma.
FRIENDSWOOD, Texas, November 15, 2022--Castle announced new data showing the independent and significant risk-stratification of DecisionDx-SCC in cSCC tumors with ambiguous histology.